A Controlled Study of Uric Acid on the Progression of IgA Nephropathy
|ClinicalTrials.gov Identifier: NCT00793585|
Recruitment Status : Completed
First Posted : November 19, 2008
Results First Posted : July 1, 2011
Last Update Posted : May 25, 2016
|Condition or disease||Intervention/treatment||Phase|
|IgA Nephropathy||Drug: allopurinol Other: continue their usual therapy||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Prospective, Randomized Controlled Study of Uric Acid on the Progression of IgA Nephropathy|
|Study Start Date :||July 2007|
|Actual Primary Completion Date :||June 2009|
|Actual Study Completion Date :||June 2009|
Allopurinol group:allopurinol, 100-300mg/d according to the levels of Scr(serum creatinine) and UA(uric acid), for those Scr < 1.5mg/dl (133 umol/L) at the baseline, allopurinol was given 100 mg three times daily.Patients diagnosed with hypertension received antihypertensive drugs with titration of CCB and β-blocker during the follow-up.The target of BP is less than 130/80mmHg.
Patients will receive the lifestyle modification and treatment of allopurinol (300 mg /d) and lifestyle modification for 4 weeks; when the UA level < 6mg/dl , the dosage changed to 200mg/d.
Control group:(patient in this group were received health education and were encouraged to adhere to a low-purine diet and continue their usual therapy.Patients diagnosed with hypertension received antihypertensive drugs with titration of CCB and β-blocker during the follow-up.The target of BP is less than 130/80mmHg.
Other: continue their usual therapy
Patients will receive lifestyle modification and continue their usual therapy.
- Change in Renal Function as Measured With eGFR [ Time Frame: baseline and 6 months ]
- The Longitudinal Change in Proteinuria and Blood Pressure(Including Changes in Antihypertensive Drugs Dosing). [ Time Frame: baseline and 6 months ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00793585
|The 1st Affiliated Hospital, Sun Yet-sen University|
|GuangZhou, Guangdong, China, 510080|
|Principal Investigator:||Xueqing Yu, M.D. & Ph.D.||1st Affiliated Hospital, Sun Yat-Sen University|